Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06989697
PHASE3

Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes

Sponsor: Seoul National University Bundang Hospital

View on ClinicalTrials.gov

Summary

This exploratory pilot study aims to evaluate the cognitive improvement effects of combination therapy with cilostazol (200 mg) and ginkgo biloba extract (160 mg) in elderly patients with type 2 diabetes mellitus. Both agents have demonstrated potential cognitive benefits through mechanisms such as enhanced cerebral blood flow, anti-inflammatory activity, and neuroprotection. Given the increased risk of cognitive decline and dementia in patients with type 2 diabetes, and the need for preventive strategies, this study will investigate whether the combination therapy can prevent or mitigate cognitive deterioration. Findings from this study may provide foundational data for the future development of therapeutic interventions targeting cognitive impairment in patients with diabetes.

Official title: Impact of Cilostazol and Ginkgo Leaf Extract on Cognitive Function in Elderly Patients With Type 2 Diabetes

Key Details

Gender

All

Age Range

60 Years - Any

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2025-01-01

Completion Date

2027-06-30

Last Updated

2025-05-25

Healthy Volunteers

No

Interventions

DRUG

Cilostazol / Ginko Leaf Dried Ext.

Patients will receive a light green, oval-shaped, sustained-release film-coated tablet containing a combination of cilostazol (200 mg) and ginkgo biloba extract (160 mg), administered orally once daily.

DRUG

Placebo

Patients will receive a placebo identical in taste, aroma, and formulation to the active treatment, administered orally once daily.

Locations (1)

Seoul National University Bundang Hospital

Seongnam-si, South Korea